- Company name
- BWX Technologies
- Sector
- Naval nuclear reactors, nuclear fuel and components for defense and power
- About
- BWX Technologies, Inc. (BWXT) is based in Lynchburg, Virginia. Its Government Operations segment makes naval nuclear reactors and their fuel for the submarines and aircraft carriers of the US Navy, under the Naval Nuclear Propulsion Program. It also processes special nuclear materials such as uranium for the US Government, and it develops advanced reactors for defense and space. Its Commercial Operations segment makes heavy components and fuel handling systems for nuclear power plants and gives services to them, including through Kinectrics, which it bought in May 2025. BWXT is the only commercial heavy nuclear component maker in North America. In Q3 2026, Government Operations had revenue of $639.1 million and Commercial Operations had $314.2 million. Revenue was $3,198 million in 2025, and the US Government was about 68% of revenue. The common stock trades on the NYSE in US dollars. BWXT files 10-K and 10-Q reports.
- Thesis
- Investors give BWXT a high multiple because it makes the nuclear reactors of US Navy submarines and aircraft carriers, and because they expect growth from new nuclear power and defense programs. Backlog was $8,556.2 million at September 30, 2026, and BWXT guides 2026 adjusted EBITDA of about $667 million, up from $574 million in 2025. Its preliminary 2027 outlook calls for high-single-digit revenue growth. The AI estimate assumes that this growth continues after 2027. For the value to rise, three things must be true. Navy budgets for submarines and aircraft carriers must stay high, so that naval propulsion work grows. Commercial Operations must turn new reactor projects and plant refurbishments into profitable growth. Advanced reactor programs, such as the US Army Janus Program, must move to paid contracts. The Q4 2026 report, expected in early February 2027, gives the 2027 guidance. If budgets or projects slip, the high multiple can fall.
- Valuation
- The intrinsic value for BWX Technologies is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of BWXT with the SEC. The method is a multiple of 2027 adjusted EBITDA, less net debt, divided by the diluted share count. The Q3 2026 release of November 2, 2026 (Form 8-K) gives 2026 guidance of about $3,800 million of revenue, about $667 million of adjusted EBITDA, non-GAAP EPS of $4.72 to $4.77 and free cash flow of $350 million to $360 million. Its preliminary 2027 outlook calls for high-single-digit revenue growth and high-single-digit to low-double-digit growth in adjusted EBITDA. It gives 92.0 million diluted shares for Q3 2026 and adjusted EBITDA of $574 million for 2025. The Q3 2026 10-Q gives 91,625,197 shares outstanding at October 30, 2026, and cash and cash equivalents of $568.5 million and debt principal of $2,050 million at September 30, 2026, so net debt is $1,481.5 million. The convertible notes due 2030 convert at about $262 per share, which is above all cases, so the estimate counts them as debt. The refinancing of November 2026 (Form 8-K of November 13, 2026) changes net debt very little. The estimate does not count the proceeds from the sale of the medical business, which is valued at up to $800 million and has not closed, and it makes no change for the earnings of that business. The 2027 adjusted EBITDA, the multiples and the weights are assumptions. The low case assumes adjusted EBITDA of $715 million, growth of about 7%, at 14 times. It gives $92.70 per share. The base case assumes $735 million, growth of about 10%, at 17 times. It gives $119.71 per share. The high case assumes $750 million, growth of about 12%, at 21 times, because new nuclear programs add growth after 2027. It gives $155.09 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $121.80 per share. BWXT makes the nuclear reactors and fuel for US Navy submarines and aircraft carriers, and its 10-K for 2025 says that it has more than 100 years of experience in supplying components for defense. It operates facilities licensed to process special nuclear materials, and it is the only commercial heavy nuclear component maker in North America. A new supplier needs many years and government approvals to replace it. The estimate counts on an advantage that lasts 20 years or more.
As of Nov 14, 2026.
- Risks
- The US Government was about 68% of revenue in 2025. Delays in the defense budget, a government shutdown or changes in Navy shipbuilding plans can reduce or delay revenue.
The price includes high expectations for growth in nuclear power and advanced reactors. If these projects come slowly, the multiple can fall.
BWXT works with nuclear materials. An accident, a safety problem or an environmental issue can stop work and add costs. Environmental liabilities were $105.8 million at September 30, 2026.
Large contracts for commercial components and first-of-a-kind reactors can have cost overruns.
The sale of the medical business needs regulatory approvals and may not close as planned in 2026 or in Q1 2027.
- Balance sheet
- Cash: $569M
Debt: $2.1B
Net debt: $1.5B
Undrawn credit line: $1.2B, to November 2030
Last debt due: 2030
At September 30, 2026, BWXT had cash and cash equivalents of $568.5 million. Long-term debt was $2,021.9 million, with principal of $2,050 million: 4.125% senior notes of $400 million due 2028 and $400 million due 2029, and 0% convertible senior notes of $1,250 million due 2030 with a conversion price of about $262 per share. The $1.25 billion revolving credit facility had no borrowings. In November 2026, BWXT issued $500 million of 6.500% senior notes due 2034, retired the notes due 2028 and 2029 with this money and cash on hand, and extended the revolving credit facility to November 10, 2031. Stockholders' equity was $1,418.3 million. Pension and postretirement liabilities were $138.0 million. Free cash flow was $150.5 million in Q3 2026.
As of Sep 30, 2026.
- Checkpoints
- Feb 2, 2027 (estimate): Q4 2026 results. Pending. Watch: 2026 non-GAAP EPS is within $4.72 to $4.77 and the 2027 guidance confirms high-single-digit revenue growth, and this passes; lower 2027 guidance fails.
Q1 2027 (estimate): Sale of the medical business. Pending. Watch: The sale to Nordic Capital closes at a value near the agreed terms, and this passes; a failed or much smaller deal fails.
Q4 2027 (estimate): Advanced reactor contracts. Pending. Watch: BWXT signs paid contracts to build Janus or other advanced reactors and its backlog grows, and this passes; delays of these programs fail.
- Recent events
- Nov 13, 2026: BWXT issued $500 million of 6.500% senior notes due 2034. With this money and cash on hand, it bought or discharged all of its 4.125% senior notes due 2028 and 2029, $800 million in total.
Nov 3, 2026: BWXT extended its $1.25 billion revolving credit facility by one year, to November 10, 2031.
Nov 2, 2026: BWXT reported Q3 2026 results. Revenue rose 10% to $953.0 million, non-GAAP EPS rose 26% to $1.26 and adjusted EBITDA was $179.7 million. It tightened its 2026 guidance to non-GAAP EPS of $4.72 to $4.77 and free cash flow of $350 million to $360 million. Its advanced reactor technology was selected for the US Army Janus Program at Fort Campbell.
Aug 3, 2026: BWXT reported Q2 2026 results, with revenue of $901.6 million and non-GAAP EPS of $1.07, and it raised its 2026 guidance. On July 31, 2026, it agreed to sell its medical business to Nordic Capital, in a deal valued at up to $800 million. On July 1, 2026, it closed the purchase of Precision Components Group.
May 4, 2026: BWXT reported Q1 2026 results, with revenue of $860.2 million and non-GAAP EPS of $1.12. It announced the purchase of Precision Components Group, which gives it a site for US commercial nuclear components.
Feb 23, 2026: BWXT reported 2025 results. Revenue was $3,198 million, non-GAAP EPS was $4.01 and backlog was $7.3 billion, up 50%. It guided 2026 non-GAAP EPS of $4.55 to $4.70.